Answers are grounded in this paper and cite their sources.
The current case series describes four previously antipsychotic-treatment naïve individuals (one had a brief prior exposure during admission) with varying background co-morbidity, presenting with first-episode psychosis/schizophrenia according to ICD-10. All received aripiprazole, brexpiprazole, or cariprazine (‘ABC’ agent) regimens early on in the course of their illness. The third generation dopamine partial agonist antipsychotics (TGA) ‘ABC’ agents have overall more benign tolerability compared to older antipsychotics but may differ in their clinical profiles and among individual patients. The case descriptions are based on retrospective medical record-derived qualitative accounts and assessments, including recurrent CGI-S ratings for semi-quantitative outcome and by the recently described Transdiagnostic Global Impression-Psychopathology (TGI-P) tool for a broadened overview of patient symptom status. The cases exemplify the diverse psychiatric and somatic comorbidities encountered in real-world clinical practice and the use of TGA already as initial treatment choice. The case series is not typical of TGA-treated patients among our outpatients but displayed a similar treatment trajectory pattern. Specifically, adverse effect (AE) issues associated with aripiprazole or brexpiprazole attempts prompted switch to cariprazine, where favourable clinical outcome was reached in all cases. It may therefore prove worthwhile trying more than one agent from this drug class even if discouraged by AE and/or poor response from a first TGA trial.
No takes yet. Share an insight, caveat, or question.
Mafi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: